Aptevo Therapeutics News and Activities

View the org chart displaying its 14 main executives

Most searched biographies at Aptevo Therapeutics

• Jeff Lamothe, Chief Executive Officer and Director
• Marvin White, Executive Chairman of the Board
• Barbara Lopez Kunz, Director

Popular executive movements at Aptevo Therapeutics

• Mary Janatpour has joined the company as Senior Vice President and Chief Scientific Officer  (posted on May 28 2026).
• Marvin White who was Director, President and Chief Executive Officer, becomes Executive Chairman of the Board  (posted on February 3 2026).
• John Niederhuber who was Chairman of the Board, becomes Lead Independent Director  (posted on February 3 2026).

Click here to view some more movements at Aptevo Therapeutics

Create your alert
to follow the executive moves at Aptevo Therapeutics.

Aptevo Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Aptevo Therapeutics

• Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia | Aptevo Therapeutics Inc
• Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights | Aptevo Therapeutics Inc
• APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting | Aptevo Therapeutics Inc
• Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | Aptevo Therapeutics Inc
• Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update | Aptevo Therapeutics Inc
• Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update | Aptevo Therapeutics Inc
• Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022 | Aptevo Therapeutics Inc
• Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial | Aptevo Therapeutics Inc
• Aptevo Therapeutics Reports Second Quarter 2020 Financial Results | Aptevo Therapeutics Inc
• Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust | Aptevo Therapeutics Inc
• View more press releases Close

Social media about Aptevo Therapeutics

• Aptevo Therapeutics on Wikipedia, Google News & Yahoo Finance
• Aptevo Therapeutics on LinkedIn, X (Twitter) & YouTube